Somatic versus Germline Mutation Assessment

Somatic versus germline assessment is the task of deciding whether a variant was inherited and present in every cell (germline) or acquired during life and confined to a tissue such as a tumour (somatic). The distinction governs how a variant is interpreted, which classification framework applies, and what it implies for relatives, so it is a foundational step in molecular interpretation.

Definition

Somatic versus germline mutation assessment is the determination of whether a detected variant is inherited and constitutional (germline) or acquired in somatic tissue (somatic), typically using comparison of tumour and normal samples and variant allele fraction, in order to apply the correct interpretive framework.

Scope

The entry covers the biological difference between somatic and germline variation, the laboratory approaches used to tell them apart, the divergence in interpretation goals between the two settings, and the implications for incidental or secondary germline findings encountered during tumour testing. It is a methodological reference topic, not clinical guidance.

Core questions

• What is the biological difference between somatic and germline variants?
• How is the origin of a variant determined in the laboratory?
• Why do somatic and germline interpretation goals differ?
• How are unexpected germline findings during tumour testing handled?

Key concepts

• Germline (constitutional) variant
• Somatic (acquired) variant
• Tumour-normal paired testing
• Variant allele fraction
• Clinical actionability (somatic)
• Heritable risk (germline)
• Incidental germline findings

Mechanisms

Germline variants are present in essentially all cells and inherited, so they appear at roughly heterozygous or homozygous allele fractions in any tissue and carry implications for blood relatives. Somatic variants arise after conception within specific cell lineages — prominently in cancer — and are typically confined to the affected tissue at variant allele fractions reflecting tumour content and clonal structure (Vogelstein et al., 2013). The most direct way to assign origin is paired tumour-normal testing, comparing the tumour to a constitutional sample; allele fraction and population databases provide supporting signals when a matched normal is unavailable. The two settings use different frameworks with different goals: the ACMG/AMP germline framework asks whether a variant causes heritable disease (Richards et al., 2015), while the AMP/ASCO/CAP framework ranks somatic variants by clinical actionability such as therapeutic relevance (Li et al., 2017). Large constitutional sequencing datasets help establish which variants are common germline background (Dewey et al., 2016).

Clinical relevance

Whether a variant is somatic or germline determines its meaning for the patient and, for germline variants, for relatives, and it shapes how findings are reported — including the handling of germline findings discovered incidentally during tumour testing. The entry explains the assessment logic and is not a basis for individual diagnosis, risk counselling, or treatment.

Evidence & guidelines

Germline interpretation follows the ACMG/AMP guideline (Richards et al., 2015) and somatic interpretation the AMP/ASCO/CAP guideline (Li et al., 2017); together they define the two frameworks whose correct selection depends on assessing variant origin. Population exome datasets characterise the background of constitutional variation (Dewey et al., 2016).

History

The somatic origin of cancer variants was established through decades of tumour genetics and consolidated by genome-scale tumour sequencing (Vogelstein et al., 2013). As tumour profiling entered routine care, the need to separate somatic from germline findings — and to manage incidental germline results — drove dedicated reporting standards, formalised for cancer in the 2017 AMP/ASCO/CAP guideline (Li et al., 2017).

Debates

How should incidental germline findings discovered during tumour testing be handled?

Tumour-only or paired testing can reveal variants that are actually germline and clinically significant for the patient and relatives; how and when to confirm, report, and refer such findings is an ongoing reporting and ethics question.

Seminal works

• vogelstein-2013
• li-2017

Frequently asked questions

What is the difference between a somatic and a germline variant?

A germline variant is inherited and present in all of a person's cells, with implications for relatives; a somatic variant is acquired during life and confined to a particular tissue, such as a tumour.

How do laboratories tell whether a variant is somatic or germline?

The most direct method is paired tumour-normal testing comparing the tumour to a constitutional sample; variant allele fraction and population databases provide supporting evidence when a matched normal sample is not available.